Inflammatory bowel diseases Genomic Medicine Consortium (iGenoMed)

Principal Investigator: John D. Rioux, Alain Bitton
Theme : Health
Competition : Genomics and Personalized Health
Status : Completed
Start : Apr. 1, 2013
End: Mar. 31, 2017
Budget : $9,892,162.00



Dawn of a new era for patients with inflammatory bowel diseases as personalized therapeutic approach may soon be here

With its 230,000 reported cases, Canada has one of the world’s highest rates of inflammatory bowel diseases (IBD), such as Crohn’s and ulcerative colitis. A variety of drugs currently exist to treat IBD, but, at the moment, doctors have no way of knowing which drug will work best for which patient. This problem is particularly important given that many new medications are expected to hit the market in the near future.


Dr. Rioux and his team are working on tests that would enable doctors to match the right drug with the right patient, avoiding the often costly and ineffective trial-and-error approach of selecting a drug. In addition to greatly improving the quality of life of those affected, this tool, once implemented, could help save the health care system several million dollars a year by avoiding costly hospitalizations and surgeries.

 

To learn more about this project, click here

 

Co-applicants and End-users:

Jean Lachaine Université de Montréal
Ramnik Xavier Mass General Hospital (Harvard), USA
Megan Levings University of British Columbia
Brian White-Guay Université de Montréal
Denis J. Garand Université Laval
Sophie  Veilleux Université Laval
Christine Des Rosiers Université de Montréal
Sylvie Lesage Université de Montréal
Guillaume Lettre Montréal Heart Institute
Mathew Harding Vertex Pharmaceuticals
Sachdev Sidhu University of Toronto
Lawrence Joseph McGill University
Lambert Busque Université de Montréal
John Parkinson Vertex Pharmaceuticals
Josée Parent Association des gastro-entérologues du Québec
Paul Sinclair Canadian Association of Gastroenterology
Aida Fernande Crohn’s and Colitis Foundation of Canada